Geron Corporation (GERN) Stock Price & Analysis
Geron Corporation (GERN) — MoonshotScore 18/100 (Weak band), calculated Nov 18, 2026. Price $0.9909 (-0.91%), as of the Nov 18, 2026 trading session; market cap $638M.
Educational signal · not a buy or sell recommendation · How to read this
Geron Corporation · GERN · NASDAQ
Geron Corporation is a late-stage clinical biopharmaceutical company focused on developing therapeutics for myeloid hematologic malignancies.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Geron (GERN)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Durable growth, but a strained balance sheet and a full valuation. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Strained; Valuation: Full; Growth Durability: Compounding; Momentum: Quiet.
- EPS beat 5 of the last 8 reports
- Altman Z -2.53 · Piotroski F 3
- ROE -20.1% · ROA -1.8% · current ratio 6.31
Holding back: balance-sheet strain
Helping: durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 18 | Weak | |
| 18 | Weak | |
| 18 | Weak | |
| 18 | Weak | |
| 18 | Weak | |
| 18 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.9909 | |
| Change on the day | -0.91% | |
| 52-week range | $0.84 – $2.01 | |
| Market capitalisation | $638M | — |
| Shares traded on the day | 34.97M |
Price & events
Other perspectives
Council score for Geron (GERN): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Simons-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Geron (GERN), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Geron Corporation (GERN) is listed on NASDAQ. It employs 258 people and is led by Harout Semerjian. The market values it at $638M.
What do the latest results show for Geron (GERN)?
Short answer · as of
Against analyst estimates the company has EPS beat 5 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $47M | -$18M | -$0.03 (diluted) |
| Q4 FY2025 | $48M | -$29M | -$0.04 (diluted) |
| Q1 FY2026 | $52M | -$4M | -$0.01 (diluted) |
| Q2 FY2026 | $57M | -$17M | -$0.02 (diluted) |
What are the financial strengths and risks for Geron (GERN)?
Short answer
The MoonshotScore pillars rate durable growth as strengths. What is holding it back is balance-sheet strain. The distress and quality screens read Altman Z -2.53 · Piotroski F 3. Trailing ratios: ROE -20.1% · ROA -1.8% · current ratio 6.31.
Data-derived red flags
- Listing risk — at $0.9909 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -2.53 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-20.1%) — the business is not currently generating profit on shareholder capital.
How does Geron compare with its peers?
Short answer
Geron's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $14.10 Nov 18, 2026 | $1.54B | 97 5-pillar Nov 18, 2026 | |
| $18.40 Nov 18, 2026 | $1.31B | 96 5-pillar Nov 18, 2026 | |
| $9.28 Nov 18, 2026 | $552M | 91 5-pillar Nov 18, 2026 | |
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $47.06 Nov 18, 2026 | $1.40B | 76 5-pillar Nov 18, 2026 | |
| $12.48 Nov 18, 2026 | $884M | 69 5-pillar Nov 18, 2026 | |
| $40.06 Nov 18, 2026 | $1.30B | 69 5-pillar Nov 18, 2026 | |
| $9.30 Nov 18, 2026 | $546M | 68 5-pillar Nov 18, 2026 | |
| $17.83 Nov 18, 2026 | $1.10B | 66 5-pillar Nov 18, 2026 | |
| $29.68 Nov 18, 2026 | $993M | 64 5-pillar Nov 18, 2026 | |
| $8.32 Nov 18, 2026 | $813M | 63 5-pillar Nov 18, 2026 | |
| Geron (GERN) — this page | $0.9909 | $638M | 18 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held GERN in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported GERN in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Geron (GERN)?
Common Questions About GERN
These answers are editorial: 1 of these 9 answers is drawn from the GERN research dossier (written Jun 13, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for GERN?
GERN carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is GERN a good stock to buy?
Stock Expert AI does not rate GERN buy, sell or hold. Geron Corporation carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the GERN stock price today?
The last price recorded for Geron Corporation (GERN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for GERN?
Geron Corporation faces several significant risks inherent to the biopharmaceutical industry, particularly as a late-stage clinical company. A primary risk is the potential for clinical trial failure, unexpected safety concerns, or a lack of demonstrated efficacy for imetelstat, which could jeopardize its path to market.
What are the key factors to evaluate for GERN?
Geron Corporation (GERN) holds a MoonshotScore in the low range. Not financial advice.
How frequently does GERN data refresh on this page?
GERN's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven GERN's recent stock price performance?
Geron Corporation (GERN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GERN overvalued or undervalued right now?
Geron Corporation (GERN) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of GERN?
Fractional-share availability for Geron Corporation (GERN) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 13, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 12 figures on this page — 4 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com